Sep 30

Artiva Biotherapeutics Demonstrates Its Commitment to Corporate Social Responsibility by Joining Pledge 1% Movement

As one of the first biotechs to join Pledge 1%, Artiva is forging a way to integrate philanthropy into a biotech company’s mission and culture

SAN DIEGO, September 30, 2021 – Artiva Biotherapeutics, Inc., (“Artiva”) announced today that it has joined Pledge 1%, a global movement that supports the integration of philanthropy into corporate culture by inspiring companies to donate 1% of product, equity, profit, or employee time to causes of their choice. Artiva is one of the first biotech companies to join the over 15,000 companies across 100 countries that have committed to philanthropic efforts through Pledge 1%.

Artiva is an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer. In addition to its efforts to develop innovative technologies designed to deliver safe and accessible therapies to cancer patients, by joining the Pledge 1%, Artiva is demonstrating its commitment to philanthropic leadership, particularly in the biotech sector.

“I am extremely proud that we have decided to join this movement,” stated Jennifer Bush, Artiva’s Chief Legal and People Officer. “Corporate social responsibility and philanthropy are integral to Artiva’s culture and our core values, and we hope to inspire other companies in the biotech industry to join the Pledge 1% movement.”

“Our team derives tremendous purpose from our mission to improve the quality of life of cancer patients and their families, and we are energized to do more,” stated Fred Aslan, M.D., Artiva’s President and CEO. “Thanks to the support of our board, we have an opportunity to help address some of the social unmet needs facing cancer patients today.”

“We are incredibly excited that Artiva has taken the pledge,” said Amy Lesnick, chief executive of Pledge 1%. “Artiva can play a pivotal role in building this movement and promoting a new normal in which all companies—including in the biotech sector—integrate giving back as a core value in their business.”

“We are delighted to confirm our commitment to corporate social responsibility through our participation in Pledge 1%,” added Brian Daniels, M.D., Chairman of Artiva.

About Pledge 1%

Pledge 1% is a global movement that inspires, educates, and empowers every entrepreneur, company, and employee to be a force for good. Over 15,000 members in 100 countries around the world have used Pledge 1%’s flexible framework to ignite billions of dollars and hundreds of thousands of volunteer hours in new philanthropy. To learn more about Pledge 1%, and how your company can get involved, visit pledge1percent.org.

About Artiva Biotherapeutics

Artiva’s mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that are safe and accessible to cancer patients. The company has entered into therapeutic NK cell collaborations and/or license agreements with Merck and with Affimed N.V. Artiva’s AlloNK™ platform incorporates cell expansion, activation, and engineering technology developed by the Company’s corporate partner, GC LabCell, a member of the GC family of companies, one of the Republic of Korea’s leading biopharmaceutical groups. Artiva is headquartered in San Diego.

Contacts

Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091

Investors: Michael E. Faerm, Artiva Biotherapeutics, Inc., mfaerm@artivabio.com

 

Recent Posts

Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting

Presentation of preclinical data for AB-101, a clinical-stage, ADCC-enhancer, allogeneic, off-the-shelf NK cell therapy candidate developed with Artiva’s AlloNKTM Platform Data highlights the optimized cell profile of AB-101 and combination data with monoclonal antibodies rituximab, obinutuzumab, cetuximab, and trastuzumab SAN DIEGO, November 10, 2022 – Artiva Biotherapeutics, Inc., a clinical stage company whose mission is...

Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101

Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patients Affimed’s AFM13 in combination with cord blood-derived NK cells demonstrated exceptionally high response rates in relapsed and refractory CD30-positive lymphoma patients AB-101 is a clinical-stage, cryopreserved, off-the shelf, non-genetically modified, allogeneic cord blood-derived NK cell manufactured at large...

Artiva Announces Abstract Accepted for Presentation at the 64th American Society of Hematology Annual Meeting & Exposition

Data describe the preclinical activity of AB-101, an allogeneic NK cell product candidate, in combination with CD38 therapeutic antibodies in multiple myeloma model systems without the need for CD38 editing SAN DIEGO, November 3, 2022 – Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK)...